Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Inclusion Criteria: * Histologically confirmed advanced solid tumor with RAS mutations identified through deoxyribonucleic acid (DNA) sequencing. * Have received prior standard therapy appropriate for tumor type and stage. * Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Adequate organ function. Exclusion Criteria: * Primary central nervous system (CNS) tumors active and untreated brain metastases. * Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication. * History of any other unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol prior/concomitant therapy